Published in Hepatitis Weekly, March 24th, 1997
Randomized, double-blind, controlled clinical trials are the gold standard for evaluating the value of medical therapies, but such trials sometimes can be generalized only to a limited extent, and where event rates are low or the events occur over an extended time period, these trials require substantial numbers of patients or long follow-up times.
Currently, there are compelling arguments for and against the treatment of patients with mild chronic hepatitis...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.